Design, Synthesis, and Evaluation of Triazole Derivatives That Induce Nrf2 Dependent Gene Products and Inhibit the Keap1-Nrf2 Protein-Protein Interaction

Hélène C. Bertrand, Marjolein Schaap, Liam Baird, Nikolaos D. Georgakopoulos, Adrian Fowkes, Clarisse Thiollier, Hiroko Kachi, Albena T. Dinkova-Kostova, Geoff Wells

Research output: Contribution to journalArticlepeer-review

Abstract

The transcription factor Nrf2 regulates the expression of a large network of cytoprotective and metabolic enzymes and proteins. Compounds that directly and reversibly inhibit the interaction between Nrf2 and its main negative regulator Keap1 are potential pharmacological agents for a range of disease types including neurodegenerative conditions and cancer. We describe the development of a series of 1,4-diphenyl-1,2,3-triazole compounds that inhibit the Nrf2-Keap1 protein-protein interaction (PPI) in vitro and in live cells and up-regulate the expression of Nrf2-dependent gene products.

Original languageEnglish (US)
Pages (from-to)7186-7194
Number of pages9
JournalJournal of Medicinal Chemistry
Volume58
Issue number18
DOIs
StatePublished - Sep 24 2015

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Medicine(all)

Fingerprint

Dive into the research topics of 'Design, Synthesis, and Evaluation of Triazole Derivatives That Induce Nrf2 Dependent Gene Products and Inhibit the Keap1-Nrf2 Protein-Protein Interaction'. Together they form a unique fingerprint.

Cite this